Congressman Tim Moore (R-N.C.) is continuing his small-capitalization stock investment strategy into 2026, building on the momentum of his 2025 trading performance. Moore's portfolio gains of 52% in the previous year significantly outpaced the S&P 500's performance, establishing his approach as a point of interest for market participants tracking congressional investment activity.
Moore's recent purchases reflect a focus on early-stage and distressed securities. The congressman has added to his position in Genprex, a gene therapy company with a market capitalization of $5.2 million that he initially acquired in 2025. Additionally, Moore has invested in Simply Good Foods, a consumer packaged goods company that has experienced considerable headwinds, declining 53% over the trailing 12-month period. These purchases suggest Moore's willingness to maintain conviction in previously held positions while deploying capital into underperforming equities.
The trading activity of Moore and other members of Congress continues to attract scrutiny from investment professionals and market observers. The alignment of legislative responsibilities with equity transactions has maintained public and institutional focus on congressional investment decisions, particularly when such activity demonstrates performance metrics that outperform broad market indices.